文献速递外周动脉疾病

定向斑块旋切联合药物涂层球囊与单用药物涂层球囊治疗股腘动脉硬化闭塞症的中期结果

Midterm Outcome of Directional Atherectomy Combined with Drug-Coated Balloon Angioplasty Versus Drug-Coated Balloon Angioplasty Alone for Femoropopliteal Arteriosclerosis Obliterans.
PubMed 文献 · Ann Vasc Surg · 2019-08-23

结果显示DA-DCB组限流性夹层发生率更低(4.4% vs 24.5%,P=0.006),技术成功率更高(95.6% vs 75.5%,P=0.006),但一期通畅率无显著差异(P=0.377)。

要点

  • DA-DCB组限流性夹层发生率显著低于DCB组(4.4% vs 24.5%,P=0.006)。
  • DA-DCB组技术成功率显著高于DCB组(95.6% vs 75.5%,P=0.006)。
  • 两组一期通畅率无显著差异(12个月80.5% vs 75.7%,24个月67.1% vs 55.1%,P=0.377)。

核心结论

  • 定向斑块旋切联合DCB可降低股腘动脉硬化闭塞症治疗中的限流性夹层率,但一期通畅率与单用DCB无显著差异。

主要发现

  • DA-DCB组限流性夹层2例(4.4%),DCB组12例(24.5%),P=0.006。
  • DA-DCB组技术成功率95.6%,DCB组75.5%,P=0.006。
  • DA-DCB组12个月和24个月一期通畅率分别为80.5%和67.1%,DCB组分别为75.7%和55.1%,但组间比较P=0.377。
  • DCB组总死亡率4.1%(2/49),DA-DCB组无死亡,无截肢。

临床怎么用

  • 对于股腘动脉硬化闭塞症,DA-DCB可减少限流性夹层并提高技术成功率,但长期通畅获益需进一步明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The "leave nothing behind" strategies have been becoming a popular treatment for femoropopliteal arteriosclerosis obliterans. Atherectomy before drug-coated balloon (DCB) angioplasty may have an advantage in improving the efficiency of drug delivery into the blood vessel wall. This study aimed to compare the therapeutic effects of directional atherectomy combined with DCB angioplasty with DCB angioplasty alone in the treatment of femoropopliteal arteriosclerosis obliterans. METHODS: Patients with femoropopliteal arteriosclerosis obliterans who received endovascular therapy from June 2016 to June 2018 in our hospital and presented with life-limiting claudication or severe chronic limb ischemia comprised the study cohort. The patients were randomized to receive directional atherectomy combined with DCB angioplasty (n = 45) or DCB alone (n = 49). Ninety-four patients were enrolled in our study with 72 males, and the mean age was 67 ± 10 years. The mean lesion length was 112 ± 64 mm. RESULTS: There were no significant differences in the baseline characteristics of patients and lesions between the 2 randomized groups (P > 0.05). Flow-limiting dissections occurred more frequently in the DCB group (n = 12; 24.5%) than in the DA-DCB group (n = 2; 4.4%; P = 0.006). The technical success rate in the DA-DCB group was superior to that in the DCB group (95.6% vs. 75.5%, P = 0.006). The mean follow-up duration was 16.7 ± 6.1 months in the DCB group and 15.3 ± 5.8 months in the DA-DCB group. No amputations were performed. The overall mortality in the DCB group was 4.1% (2/49), while all patients survived in the DA-DCB group. The 12-month and 24-month primary patencies in the DA-DCB group were greater than those in the DCB group (80.5% vs. 75.7% and 67.1% vs. 55.1%, respectively); however, using all available patency data, no significant differences over time were observed (P = 0.377). CONCLUSIONS: In this study, directional atherectomy combined with DCB angioplasty can decrease the flow-limiting dissection rate in the treatment of femoropopliteal arteriosclerosis obliterans compared with DCB angioplasty alone. There was no significant difference between the 2 groups in terms of primary patency rate which was needed to be further clarified.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Cai Z, Guo L, Qi L, et al. Midterm Outcome of Directional Atherectomy Combined with Drug-Coated Balloon Angioplasty Versus Drug-Coated Balloon Angioplasty Alone for Femoropopliteal Arteriosclerosis Obliterans. Ann Vasc Surg. 2019. PMID: 31449956. doi:10.1016/j.avsg.2019.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。